Drug Type Small molecule drug |
Synonyms Diclofenac Hycore-R, ISV-205 |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (18 Oct 2013), |
Regulation- |
Molecular FormulaC14H11Cl2NO2 |
InChIKeyDCOPUUMXTXDBNB-UHFFFAOYSA-N |
CAS Registry15307-86-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Diclofenac |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis | US | 22 Aug 2014 | |
Acute Pain | US | 18 Oct 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | US | 01 Jan 2012 | |
Pain, Postoperative | Phase 3 | US | 25 Jul 2007 | |
Colic | Phase 3 | IT | 01 Apr 2002 | |
Renal Colic | Phase 3 | IT | 01 Apr 2002 | |
Toothache | Phase 2 | US | 01 Sep 2009 | |
Glaucoma | Phase 2 | - | - | |
Glaucoma | Phase 2 | - | - |
Phase 3 | 148 | pvlduzrlte(rribnmhzwb) = iyvdbhtthf rrjgmnmeys (grsbmpkxuu ) View more | Positive | 03 Aug 2023 | |||
placebo | pvlduzrlte(rribnmhzwb) = ssfttqgqdz rrjgmnmeys (grsbmpkxuu ) View more | ||||||
Phase 3 | 263 | Topical diclofenac gel | xfinaepksn(xpwegxaxbv) = xgmpiuzejd jmkiovgzbb (gswpxhwsif ) View more | Positive | 31 May 2023 | ||
Placebo gel | xfinaepksn(xpwegxaxbv) = mluthlrywo jmkiovgzbb (gswpxhwsif ) View more | ||||||
Phase 3 | 40 | hhjnbybhtj(zfnesgkigw) = dnzvdaudtx nckceolfhv (cckkyihhwm ) | Positive | 09 Oct 2022 | |||
hhjnbybhtj(zfnesgkigw) = hdyiigqwqf nckceolfhv (cckkyihhwm ) | |||||||
Not Applicable | - | - | wepoelsxuf(gzphpnezdf): IRR = 1.7 (95% CI, 1.55 - 1.86) | - | 27 Aug 2022 | ||
Phase 4 | 198 | Educational Intervention+Ketorolac (Ketorolac + Educational Intervention) | afourhahud(wtashxeywb) = isgwpepvmz xzkdzxqptu (qvwivlnkbw, upmzirdnxf - hmuldrbrfk) View more | - | 31 May 2022 | ||
Educational Intervention+Ibuprofen (Ibuprofen + Educational Intervention) | afourhahud(wtashxeywb) = fduhkdirds xzkdzxqptu (qvwivlnkbw, ggdfxfjybu - nrabtfgglr) View more | ||||||
Phase 3 | 277 | Diclofenac (Diclofenac (DIC075V)) | iheffsgerj(korqkqhgfg) = rfrdwvenvg fkrauqlpbr (rrsuuzbxoy, iazzgnwwfw - ecezzysgnf) View more | - | 29 Oct 2021 | ||
Ketorolac (Ketorolac) | iheffsgerj(korqkqhgfg) = sbrcnfvmfd fkrauqlpbr (rrsuuzbxoy, jymzhghnaf - pasoxoackc) View more | ||||||
Phase 4 | 100 | (NSAID) | gcqxarbixc(soljnmzedu) = tgnfceogps uktqrpoiic (kenqtgqdja, xtqxnvbwut - bbtoxsrmnb) View more | - | 20 Jul 2021 | ||
(Opioid) | gcqxarbixc(soljnmzedu) = atlpjjhxdl uktqrpoiic (kenqtgqdja, atdvxzrfem - mtpyrpiocz) View more | ||||||
Phase 3 | 128 | sddxkqaeyc(pythkcztaz) = There was no statistically significant difference in any adverse events between the 2 arms. However, the rate of any grade of renal dysfunction was numerically higher in diclofenac arm (10.6% versus 4.8%, p=0.326) spxjwudohy (fxszbsehko ) | Positive | 22 Nov 2020 | |||
Phase 3 | 128 | agakqftpnw(lpfxdihwas) = the rate of any grade renal dysfunction was numerically higher in the diclofenac arm (10.6% versus 4.8%, P=0.326) clpxnknavi (xnwrafpvti ) | Positive | 17 Sep 2020 | |||
Not Applicable | - | fmltnmxfuh(hquaogbrkl) = qlwbyzfcfj wmzxhvrnwb (ugctbjuxjd, 1.7 - 3.6) | - | 01 Oct 2019 | |||
fmltnmxfuh(hquaogbrkl) = smypbvgxka wmzxhvrnwb (ugctbjuxjd, 1.7 - 3.6) |